Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors
- PMID: 2280797
- DOI: 10.1007/BF00169441
Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors
Abstract
The interaction of locally perfused cholecystokinin-8 (sulphated) with systemically administered apomorphine was studied on the release of dopamine and its metabolites using microdialysis in the neostriatum of the halothane-anaesthetized male rat. Dialysate levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid were assayed by high performance liquid chromatography in combination with electrochemical detection. Perfusion with cholecystokinin-8 (100 microM but not 1 microM or 10 nM) increased the dialysate levels of dopamine without affecting those of DOPAC or HVA. At low concentrations (1 microM and 10 nM but not 1 nM), cholecystokinin-8 counteracted the inhibitory effect of apomorphine (0.05 mg/kg, s.c.) on dopamine release. This counteraction was antagonized by perfusion with the cholecystokinin-8 antagonist proglumide (3 microM). At this concentration, proglumide perfused alone was without effect on basal or apomorphine-reduced levels of dopamine. The results indicate a facilitatory effect of cholecystokinin-8 on dopamine release in rat neostriatum only at high concentrations. At lower concentrations, cholecystokinin-8 appears to modulate dopamine release by an inhibitory effect on dopamine autoreceptors possibly involving an intramembrane interaction between presynaptic cholecystokinin-8 receptors and dopamine autoreceptors.
Similar articles
-
Changes in pituitary-adrenal activity affect the apomorphine- and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis.J Neural Transm Gen Sect. 1990;81(3):183-94. doi: 10.1007/BF01245041. J Neural Transm Gen Sect. 1990. PMID: 2397084
-
Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum.Brain Res. 1989 Nov 20;502(2):319-24. doi: 10.1016/0006-8993(89)90627-6. Brain Res. 1989. PMID: 2819469
-
Effects of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method.J Neurochem. 1989 Dec;53(6):1861-4. doi: 10.1111/j.1471-4159.1989.tb09253.x. J Neurochem. 1989. PMID: 2809596
-
Modulation of motor behaviour by NMDA- and cholecystokinin-antagonism.Amino Acids. 1998;14(1-3):25-31. doi: 10.1007/BF01345238. Amino Acids. 1998. PMID: 9871437 Review.
-
Cholecystokinin receptors in relation to brain dopaminergic pathways.Neurochem Int. 1992 Mar;20 Suppl:339S-343S. doi: 10.1016/0197-0186(92)90262-p. Neurochem Int. 1992. PMID: 1365453 Review. No abstract available.
Cited by
-
Receptor-receptor interactions as an integrative mechanism in nerve cells.Mol Neurobiol. 1993 Fall-Winter;7(3-4):293-334. doi: 10.1007/BF02769180. Mol Neurobiol. 1993. PMID: 7514001 Review.
-
Changes in pituitary-adrenal activity affect the apomorphine- and cholecystokinin-8-induced changes in striatal dopamine release using microdialysis.J Neural Transm Gen Sect. 1990;81(3):183-94. doi: 10.1007/BF01245041. J Neural Transm Gen Sect. 1990. PMID: 2397084
-
Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):102-7. doi: 10.1007/BF00168544. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8397341
-
Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization.Front Endocrinol (Lausanne). 2014 May 13;5:71. doi: 10.3389/fendo.2014.00071. eCollection 2014. Front Endocrinol (Lausanne). 2014. PMID: 24860548 Free PMC article. Review.